George S. Zorich Named Chief Executive Officer of Agilis Biotherapeutics

  George S. Zorich Named Chief Executive Officer of Agilis Biotherapeutics

Business Wire

NEW YORK -- December 31, 2013

Agilis Biotherapeutics, LLC, a synthetic biology-based company focused on
developing DNA-based therapeutics for rare genetic diseases, announced today
that George S. Zorich has been named Chief Executive Officer of the company.
Mr. Zorich previously served as President of General Injectables and Vaccines,
Inc. (GIV), President of U.S. operations for Sabex USA, and President of North
American operations for Bioniche Pharma, three enterprises that were sold to
global pharmaceutical companies under Mr. Zorich’s leadership. Mr. Zorich
began his career with Eli Lilly and Company and has held various executive
positions across a variety of businesses, including branded products,
generics, and distribution.

“Agilis is thrilled to have George join our efforts in developing new
therapies for rare diseases utilizing synthetic biology approaches,” said G.
Houston Hall, Managing Director of Agilis Biotherapeutics. “George is a highly
accomplished leader who brings to Agilis both strategic vision and a track
record of significant operating results. Agilis is well-positioned to advance
our Friedreich’s ataxia program with our collaborator Intrexon Corporation
(NYSE: XON). I cannot imagine a better person to add to our team, and I look
forward to working closely with George in the development of life changing
medicines.”

“It is a very exciting time at Agilis,” said Mr. Zorich. “I’m delighted to be
joining this team of highly regarded researchers and business leaders and
working in collaboration with Intrexon to potentially develop novel approaches
to treating rare genetic diseases with synthetic biology. I look forward to
helping the team move rapidly towards key development decisions with a very
exciting DNA-based therapeutic.”

About Agilis Biotherapeutics, LLC

Agilis Biotherapeutics, LLC, is a biotechnology company focused on designing
and engineering first-in-class DNA-based therapeutics to improve and save the
lives of patients affected by life-threatening or fatal rare diseases for
which there are limited or no treatment options. We believe that engineered
DNA-based therapeutics provide the ability to target underlying disease
mechanisms with tightly-controlled multigenic modalities leading to
“functional cures” for patients with these diseases.

We invite you to visit our website at www.agilisbio.com.

Safe Harbor Statement

Some of the statements made in this press release are forward-looking
statements. These forward-looking statements are based upon our current
expectations and projections about future events and generally relate to our
plans, objectives and expectations for the development of our business.
Although management believes that the plans and objectives reflected in or
suggested by these forward-looking statements are reasonable, all
forward-looking statements involve risks and uncertainties and actual future
results may be materially different from the plans, objectives and
expectations expressed in this press release.

Contact:

Agilis Biotherapeutics
George S. Zorich, 301-944-2884
Chief Executive Officer
info@agilisbio.com
 
Press spacebar to pause and continue. Press esc to stop.